ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Quick Ratio
- Quick ratio · latest quarter: Value 4.49×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.49× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $393.77M ÷ $87.71M ≈ 4.49× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 393.77M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 87.71M USD | Liabilities, Current |
| Cash and equivalents | 169.87M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 174.38M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 49.51M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 10.50M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $393.77M | $87.71M | $169.87M | $174.38M | $49.51M | $10.50M | 4.49× |
| 2026-03-31 | $266.65M | $87.01M | $77.58M | $140.75M | $48.31M | $11.21M | 3.06× |
| 2025-12-31 | $277.35M | $89.92M | $70.50M | $156.49M | $50.37M | $9.82M | 3.08× |
| 2025-09-30 | $257.59M | $83.36M | $55.03M | $157.74M | $44.82M | $9.93M | 3.09× |
| 2025-06-30 | $242.16M | $92.14M | $43.16M | $154.71M | $44.28M | $8.40M | 2.63× |
| 2025-03-31 | $237.01M | $87.81M | $50.65M | $142.78M | $43.58M | $8.68M | 2.70× |
| 2024-12-31 | $264.02M | $98.05M | $47.92M | $174.37M | $41.73M | $8.44M | 2.69× |
| 2024-09-30 | $284.14M | $87.63M | $38.08M | $205.25M | $40.81M | $11.96M | 3.24× |
| 2024-06-30 | $327.49M | $88.13M | $59.82M | $232.06M | $35.61M | $13.21M | 3.72× |
| 2024-03-31 | $350.89M | $82.95M | $71.23M | $237.64M | $42.02M | $13.29M | 4.23× |
| 2023-12-31 | $384.37M | $88.02M | $65.06M | $281.34M | $37.97M | $14.45M | 4.37× |
| 2023-09-30 | $402.34M | $93.30M | $88.71M | $282.42M | $31.21M | $19.49M | 4.31× |
| 2023-06-30 | $448.77M | $95.33M | $109.24M | $307.99M | $31.55M | $18.96M | 4.71× |
| 2023-03-31 | $471.67M | $90.10M | $94.61M | $346.08M | $30.97M | $19.87M | 5.23× |
| 2022-12-31 | $538.25M | $109.79M | $90.03M | $408.17M | $40.06M | $14.45M | 4.90× |
| 2022-09-30 | $534.63M | $104.02M | $217.55M | $290.53M | $26.55M | $17.34M | 5.14× |
| 2022-06-30 | $407.45M | $111.47M | $76.41M | $307.33M | $23.71M | $18.78M | 3.66× |
| 2022-03-31 | $386.08M | $115.07M | $114.81M | $248.76M | $22.52M | $21.00M | 3.36× |
| 2021-12-31 | $370.47M | $113.81M | $139.06M | $214.00M | $17.41M | $19.26M | 3.26× |
| 2021-09-30 | $432.16M | $122.38M | $122.40M | $292.64M | $17.12M | $18.23M | 3.53× |
| 2021-06-30 | $612.59M | $116.65M | $184.19M | $414.23M | $14.17M | $18.61M | 5.25× |
| 2021-03-31 | $734.02M | $106.77M | $173.62M | $540.64M | $19.75M | $17.42M | 6.87× |
| 2020-12-31 | $698.32M | $105.20M | $123.44M | $564.83M | $10.05M | $14.06M | 6.64× |
| 2020-09-30 | $846.94M | $100.83M | $497.08M | $338.00M | $11.86M | $10.74M | 8.40× |
| 2020-06-30 | $578.29M | $93.42M | $365.44M | $204.94M | $7.91M | $10.54M | 6.19× |
| 2020-03-31 | $564.55M | $77.95M | $212.69M | $342.49M | $9.38M | $10.52M | 7.24× |
| 2019-12-31 | $589.54M | $78.31M | $96.58M | $480.29M | $12.68M | $9.07M | 7.53× |
| 2019-09-30 | $582.68M | $73.38M | $74.94M | $498.49M | $9.26M | $8.67M | 7.94× |
| 2019-06-30 | $430.25M | $74.86M | $48.46M | $374.54M | $7.25M | $8.00M | 5.75× |
| 2018-12-31 | $169.82M | $22.80M | $55.03M | $109.99M | $4.81M | $7.84M | 7.45× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |